Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 10.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,945 shares of the company's stock after selling 26,817 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.78% of Krystal Biotech worth $40,947,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of KRYS. Key Financial Inc purchased a new stake in Krystal Biotech during the 2nd quarter valued at $28,000. GAMMA Investing LLC lifted its stake in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after acquiring an additional 93 shares during the period. Jamison Private Wealth Management Inc. bought a new position in shares of Krystal Biotech during the second quarter valued at approximately $28,000. Blue Trust Inc. boosted its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in Krystal Biotech during the third quarter valued at about $53,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on KRYS shares. Citigroup lifted their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. William Blair upgraded shares of Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Evercore ISI upped their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Stifel Nicolaus raised their target price on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $202.29.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 1.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 14.10% of the company's stock.

Krystal Biotech Stock Up 1.0 %

Shares of Krystal Biotech stock traded up $1.86 on Wednesday, reaching $187.83. The company's stock had a trading volume of 143,822 shares, compared to its average volume of 322,969. Krystal Biotech, Inc. has a 52-week low of $100.98 and a 52-week high of $219.34. The company has a market capitalization of $5.40 billion, a P/E ratio of 105.73 and a beta of 0.80. The stock has a 50-day moving average price of $180.92 and a 200-day moving average price of $184.26.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to analysts' expectations of $82.94 million. During the same period in the prior year, the business posted ($0.67) earnings per share. The firm's revenue for the quarter was up 879.9% on a year-over-year basis. Sell-side analysts forecast that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).